New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2013
08:48 EDTCLDXCelldex announces CDX-301 combination study 'positive' results
Celldex Therapeutics announces "positive" results from a preclinical combination study of CDX-301 and Mozobil demonstrating that the combination of these agents significantly increases hematopoietic stem cell mobilization in mice. The data support future clinical development of CDX-301 and demonstrate a potent cell mobilization regimen combining CDX-301 and Mozobil, which may have significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation. The company said, "We plan to initiate a pilot clinical study evaluating CDX-301 alone and in combination with Mozobil in the transplant setting in early 2014 and look forward to seeing how this program progresses."
News For CLDX From The Last 14 Days
Check below for free stories on CLDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
14:02 EDTCLDXCelldex Phase 1 study of CDX-1401 demonstrates robust antibody response
Subscribe for More Information
April 15, 2014
08:19 EDTCLDXLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use